<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769181</url>
  </required_header>
  <id_info>
    <org_study_id>ACT15320</org_study_id>
    <secondary_id>2018‐002442‐37</secondary_id>
    <secondary_id>U1111-1211-9010</secondary_id>
    <nct_id>NCT03769181</nct_id>
  </id_info>
  <brief_title>A Study of Isatuximab-based Therapy in Participants With Lymphoma</brief_title>
  <official_title>A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      Phase 1

      -To characterize the safety and tolerability of isatuximab in combination with cemiplimab in
      participants with relapsed and refractory classic Hodgkin's lymphoma (cHL), diffuse large
      B-cell lymphoma (DLBCL) or peripheral T-cell lymphoma (PTCL), and to confirm the recommended
      Phase 2 dose (RP2D).

      Phase 2

        -  Cohort A1 (anti-programmed cell death protein 1/ligand 1 [PD-1/PD-L1] naïve cHL): To
           assess the complete remission (CR) rate of isatuximab in combination with cemiplimab.

        -  Cohort A2 (cHL progressing from PD-1/PD-L1), B (DLBCL) and C (PTCL): To assess the
           objective response rate (ORR) of isatuximab in combination with cemiplimab.

      Secondary Objectives:

        -  To evaluate the safety of the RP2D of the combination of isatuximab with cemiplimab.

        -  To evaluate the safety of the combination of isatuximab with cemiplimab and radiotherapy
           in patients with cHL.

        -  To evaluate the immunogenicity of isatuximab and cemiplimab when given in combination.

        -  To characterize the pharmacokinetic (PK) profile of isatuximab and cemiplimab when given
           in combination.

        -  To assess overall efficacy of isatuximab in combination with cemiplimab and isatuximab
           in combination with cemiplimab and radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient is up to 28 months, including an up to 28-day screening
      period, an up to 96-week treatment period, and a 90-day safety follow up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Dose limiting toxicities (DLTs); Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>1st Cycle - 28 days</time_frame>
    <description>DLTs as observed during DLT-observation period; Dose selected for the Phase 2 portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Cohort A1 (anti-PD-1/PD-L1 naive cHL): Complete Remission Rate</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The proportion of participants who have a Complete Remission as a best overall response during the isatuximab + cemiplimab therapy period using the Lugano response criteria 2014</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Cohort A2 (cHL progressing from PD-1/PD-L1), B (DLBCL) and C (PTCL): Response Rate</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The proportion of participants who have a Complete Response or Partial Response as a best overall response during isatuximab + cemiplimab therapy period using the Lugano response criteria 2014</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)/Serious Adverse Events (SAEs) for isatuximab + cemiplimab</measure>
    <time_frame>Up to 90 days after last study treatment administration (Up to approximately 27 months after first study treatment administration)</time_frame>
    <description>Number of patients with AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events/Serious Adverse Events for isatuximab + cemiplimab + radiotherapy</measure>
    <time_frame>Up to 90 days after last study treatment administration (Up to approximately 27 months after first study treatment administration)</time_frame>
    <description>Number of patients with AEs/SAEs in cohorts A1 and A2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Anti-drug antibody levels</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Anti-drug antibody (ADA) levels against isatuximab and against cemiplimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Cmax</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Maximum concentration observed after the first infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Ctrough</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Concentrations observed just before treatment administration during repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: AUC0-T</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Area under the concentration versus time curve calculated using the trapezoidal method over the dosing interval (ie, 6 days for isatuximab or 21 days for cemiplimab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor burden change</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The best percent-change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The sum of complete responses (CR) + partial responses (PR) + stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The time from the date of the first response (PR or CR in radiographic objective response) that is subsequently confirmed to the date of first confirmed disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The time from the first study treatment administration to the date of first documentation of progressive disease or death, whichever comes first</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: cHl/DLBCL/PTCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Phase 1: cHl/DLBCL/PTCL</arm_group_label>
    <arm_group_label>Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor</arm_group_label>
    <arm_group_label>Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <other_name>Sarclisa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cemiplimab REGN2810</intervention_name>
    <description>Pharmaceutical form: solution for infusion
Route of administration: intravenous</description>
    <arm_group_label>Phase 1: cHl/DLBCL/PTCL</arm_group_label>
    <arm_group_label>Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor</arm_group_label>
    <arm_group_label>Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participants must be ≥ 12 years of age inclusive, at the time of signing the informed
             consent

          -  Disease location amenable to tumor biopsy at baseline

          -  Measurable disease

          -  For Cohort A1 (classic Hodgkin's lymphoma [cHL] anti-programmed cell death protein
             1/ligand 1 [PD-1/PD-L1] inhibitor naïve): Histologically confirmed advanced cHL that
             has relapsed or progressed after at least 3 lines of systemic therapy that may include
             autologous hematopoietic stem cell transplant (auto-HSCT) or auto-HSCT and brentuximab
             vedotin (BV)

          -  For Cohort A2 (cHL anti-PD-1/PD-L1 inhibitor progressor): Histologically confirmed
             advanced cHL which has relapsed or progressed after one previous anti-PD-1/PD-L1
             containing regimen as the most recent prior therapy but no more than 4 lines of
             previous chemotherapy including the anti-PD-1/PD-L1 containing regimen and
             documentation of benefit during or after the anti-PD-1/PD-L1 containing regimen within
             4 months prior to initiation of investigational medicinal product (IMP)

          -  For Cohort B (diffuse large B-cell lymphoma [DLBCL]): Histologically confirmed
             advanced DLBCL that has relapsed or progressed after 2 lines of systemic therapy
             including auto-HSCT or 2 lines of systemic therapy for participants who are not
             eligible for auto-HSCT

          -  For Cohort C (peripheral T-cell lymphoma [PTCL]): Histologically confirmed advanced
             PTCL that has relapsed or progressed after either first-line chemotherapy and
             auto-HSCT as consolidation of first remission or first-line chemotherapy if
             participants are ineligible for auto-HSCT

          -  Body weight of &gt; 45 kg for patients with age &lt;18 years

        Exclusion criteria:

          -  Prior exposure to agent that blocks CD38

          -  For patients with cHL (PD-1/PD-L1 naïve), DLBCL or PTCL prior exposure to any agent
             (approved or investigational) that blocks the PD-1/PD-L1, PD-L2, CD137, CTLA-4 or
             LAG-3

          -  Evidence of other immune related disease/conditions

          -  Has received a live-virus vaccination within 28 days of planned treatment start;
             seasonal flu vaccines that do not contain live virus are permitted

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2

          -  Poor bone marrow reserve

          -  Poor organ function

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 2500006</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500008</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Nantes Cedex 01</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500007</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800006</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100001</name>
      <address>
        <city>Gangnam-Gu</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100002</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4100003</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280002</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5280001</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200002</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200004</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6200003</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240005</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240004</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580003</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580002</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1580001</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-CD38 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

